James B. Whitney

James B. Whitney

Auto-generated profile, based on publicly available information

James B. Whitney

Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2016 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
COChrista E Osuna
Christa E Osuna
SLSo-Yon Lim
So-Yon Lim
CDClaire Deleage
Claire Deleage
BGBryan D Griffin
Bryan D Griffin
DSDerek Stein
Derek Stein
JWJames B Whitney
James B Whitney

2 May 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SLSo-Yon Lim
So-Yon Lim
COChrista E. Osuna
Christa E. Osuna
PHPeter Hraber
Peter Hraber
JHJoe Hesselgesser
Joe Hesselgesser
JGJeffrey M. Gerold
Jeffrey M. Gerold
JWJames B. Whitney
James B. Whitney
Antiretroviral therapy (ART) can halt HIV-1 replication but fails to target the long-lived latent viral reservoir. Several pharmacological compounds have been evaluated for their ability to reverse HIV-1 latency, but none has demonstrably reduced the latent HIV-1 reservoir or affected viral rebound after the interruption of ART. We evaluated orally administered selective Toll-like receptor 7 (TLR7) agonists GS-986 and GS-9620 for their ability to induce transient viremia in rhesus macaques infected with simian immunodeficiency virus (SIV) and treated with suppressive ART. In an initial dose-escalation study, and a subsequent dose-optimization study, we found that TLR7 agonists activated multiple innate and adaptive immune cell populations in addition to inducing expression of SIV RNA. We also observed TLR7 agonist–induced reductions in SIV DNA and measured inducible virus from treated animals in ex vivo cell cultures. In a second study, after stopping ART, two of nine treated animals remained aviremic for more than 2 years, even after in vivo CD8+ T cell depletion. Moreover, adoptive transfer of cells from aviremic animals could not induce de novo infection in naïve recipient macaques. These findings suggest that TLR7 agonists may facilitate reduction of the viral reservoir in a subset of SIV-infected rhesus macaques.

21 December 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJames B. Whitney
James B. Whitney
SLSo-Yon Lim
So-Yon Lim
COChrista E. Osuna
Christa E. Osuna
JKJessica L. Kublin
Jessica L. Kublin
ECElsa Chen
Elsa Chen
DBDan H. Barouch
Dan H. Barouch
The precise time when the viral reservoir is seeded during acute HIV-1 infection remains unclear. We previously demonstrated that the viral reservoir was seeded by day 3 following SIVmac251 infection in rhesus monkeys. Here we report the impact of initiating ART on day 0 (6 h), 1, 2, or 3 following intrarectal SIVmac251 infection in 20 rhesus monkeys (N = 5/group). After 6 months of daily suppressive ART, antiretroviral drugs were discontinued, and viral rebound was monitored. 0% (0 of 5), 20% (1 of 5), 60% (3 of 5), and 100% (5 of 5) of animals that initiated ART on days 0 (6 h), 1, 2, or 3, respectively, showed viral rebound following ART discontinuation and correlated with integrated viral DNA in lymph node CD4+ T cells. These data demonstrate that the viral reservoir is seeded within the first few days of infection and that early ART initiation limits the viral reservoir.

19 September 2018 in Nature
Verified
Journal Article
Closed access
PDF file
COChrista E. Osuna
Christa E. Osuna
SLSo-Yon Lim
So-Yon Lim
JKJessica L. Kublin
Jessica L. Kublin
RARichard Apps
Richard Apps
ECElsa Chen
Elsa Chen
JWJames B. Whitney
James B. Whitney

8 March 2024 in Science
Verified
Journal Article
Open access
SLSo-Yon Lim
So-Yon Lim
JLJina Lee
Jina Lee
COChrista E. Osuna
Christa E. Osuna
PVPratik Vikhe
Pratik Vikhe
DSDane R. Schalk
Dane R. Schalk
JWJames B. Whitney
James B. Whitney
The eradication of the viral reservoir represents the major obstacle to the development of a clinical cure for established HIV-1 infection. Here, we demonstrate that the administration of N-803 (brand name Anktiva) and broadly neutralizing antibodies (bNAbs) results in sustained viral control after discontinuation of antiretroviral therapy (ART) in simian-human AD8 (SHIV-AD8)–infected, ART-suppressed rhesus macaques. N-803+bNAbs treatment induced immune activation and transient viremia but only limited reductions in the SHIV reservoir. Upon ART discontinuation, viral rebound occurred in all animals, which was followed by durable control in approximately 70% of all N-803+bNAb–treated macaques. Viral control was correlated with the reprogramming of CD8 + T cells by N-803+bNAb synergy. Thus, complete eradication of the replication-competent viral reservoir is likely not a prerequisite for the induction of sustained remission after discontinuation of ART.

15 December 2017 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
COChrista E Osuna
Christa E Osuna
JWJames B Whitney
James B Whitney
Zika virus is a re-emerging flavivirus transmitted primarily by arthropod vectors. The recent devastating outbreak of Zika virus in Brazil was preceded by the slow global encroachment of this virus over many decades. To date, significant research efforts are underway to understand the spread and the unique pathogenesis of this virus; with the intent to rapidly develop vaccines and therapeutics. Several model systems have emerged to study Zika. This review will focus on the use of nonhuman primates to model Zika infection.